Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: A critical appraisal

British Journal of Dermatology

Volumn 166, Issue 4, 2012, Pages 704-

  Schram, M E ^a   Roekevisch, E ^a   Leeflang, M M G ^a   Bos, J D ^a   Schmitt, J ^b   Spuls, P I ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHOTREXATE; STEROID;

ATOPIC DERMATITIS; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STEROID THERAPY;

EID: 84859138323     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10874.x     Document Type: Note

References (3)

1. Patel AN, Langan SM, Batchelor JM,. A randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal. Br J Dermatol 2012; 166: 701-4.
2. Schram ME, Roekevisch E, Leeflang MMG, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128: 353-9.
3. Schram ME, Spuls PI, Leeflang MMG, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106.